After demonstrating the superior antitumor efficacy of IL-7–CBD over unmodified IL-7 in the MC38 model, which is known to be CPI-responsive (27, 28), we sought to combine it with CBD–IL-12 (23) and assess the efficacy of the combination therapy in the CPI-unresponsive B16F10 melanoma model (Fig. 1C and fig. Here, IL7 is linked to melanoma.